

SEP extends distribution agreement for Regurin XL in the United Kingdom

Speciality European Pharma Limited (“SEP”) is pleased to announce that on 20 December 2016 it entered into an agreement with Madaus GmbH, part of the Mylan group of companies, pursuant to which it extended its distribution agreement for Regurin[®] XL in the United Kingdom by a further two years.

Regurin[®] XL is a pharmaceutical product indicated to help the symptoms of overactive bladder. SEP has been the distributor of Regurin[®] XL in the United Kingdom since the product's launch in September 2009. Under the terms of the original distribution agreement for the product, SEP's distribution rights had been due to expire in mid 2017. This new agreement extends SEP's distribution rights through mid-2019.

Commenting on the extension, Rakesh Tailor, Chief Operating Officer of SEP, said:

“Regurin[®] XL was one of SEP's first products, licensed from Madaus GmbH, now part of the Mylan group of companies, in May 2009. SEP launched the product onto the UK market in September 2009 and it has been a considerable success for the company. Regurin[®] XL compliments SEP's other major product offering in the UK market, Bulkamid[®], its treatment for stress urinary incontinence.”

About Regurin[®] XL

Regurin[®] XL is a pharmaceutical product indicated for the symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder. It is a prolonged release formulation of the active ingredient, trospium chloride and is one of the anticholinergics recommended by NICE for the treatment of urinary incontinence in women. The product is licensed from Madaus GmbH, a member of the Mylan group of companies. Further details can be found on the SPC at <https://www.medicines.org.uk/emc/medicine/22236>.

About Bulkamid[®]

Bulkamid[®] is a homogenous hydrophilic hydrogel used in the treatment of female stress urinary incontinence. The product was granted CE approval in 2003 and is currently sold in more than 20 countries worldwide. Bulkamid[®] is delivered to the patient under endoscopic control using the Bulkamid[®] Urethral Bulking System.

About SEP

SEP is the parent company of a European group which specialises in the distribution and sale of healthcare products, both pharmaceuticals and medical devices, focused primarily upon the fields of urology and urogynaecology. Its lead products are:

Bulkamid[®]
Aquamid[®]
Mitem[®]
Regurin[®] XL
Cystistat[®]

SEP was founded in 2006 and built an experienced and accomplished management team. In 2013, SEP acquired Contura A/S, a Danish company based in Copenhagen. Contura A/S had two marketed products at the time of its acquisition by SEP, Bulkamid[®] and Aquamid[®]. It also had a number of development programmes focused upon additional uses of its hydrogel technology. SEP has established a sales and marketing infrastructure in the leading European markets, either through its own sales force or through distribution partners. SEP has offices in the UK, Denmark, Germany, France and Italy.

-ENDS-

For further information please contact:

SEP
Patrick Banks, Chief Executive Officer

Tel: +44 (0)20 7421 7400